Alnylam Pharmaceuticals | ALNY - Net Income

Stock Price
331.24
Daily Change
-20.72 -5.89%
Monthly
-18.49%
Yearly
19.04%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $251.08M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Arrowhead Research USD -23.75M 151.49M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 113M Sep/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Takeda JPY 103.64B 115.44B Dec/2025
Tectonic Therapeutic USD -19.04M 940K Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025
Xencor USD -6.03M 24.8M Sep/2025